> top > projects > sonoma > docs > PubMed:16371368 > annotations
sonoma  

PubMed:16371368 JSONTXT 55 Projects

Annnotations TAB TSV DIC JSON TextAE Lectin_function IAV-Glycan

Id Subject Object Predicate Lexical cue
T-0 0-7 REG denotes Effects
T-1 33-49 POSREG denotes gain-of-function
T-2 50-58 VAR denotes mutation
T-3 62-79 GENE denotes SHP-2 phosphatase
T-4 108-117 VAR denotes Mutations
T-5 121-138 GENE denotes SHP-2 phosphatase
T-6 144-149 REG denotes cause
T-7 150-165 POSREG denotes hyperactivation
T-8 173-191 MPA denotes catalytic activity
T-9 202-212 REG denotes identified
T-10 222-231 DISEASE denotes leukemias
T-11 246-278 DISEASE denotes juvenile myelomonocytic leukemia
T-12 289-302 REG denotes characterized
T-13 306-322 POSREG denotes hypersensitivity
T-14 470-486 POSREG denotes gain-of-function
T-15 488-491 POSREG denotes GOF
T-16 493-502 VAR denotes mutations
T-17 506-511 GENE denotes SHP-2
T-18 512-518 REG denotes induce
T-19 519-545 DISEASE denotes hematopoietic malignancies
T-20 609-614 GENE denotes SHP-2
T-21 729-743 POSREG denotes overexpression
T-22 773-778 GENE denotes SHP-2
T-23 779-789 NEGREG denotes attenuates
T-24 804-831 CPA denotes hematopoietic cell function
T-25 840-851 POSREG denotes accelerated
T-26 852-869 MPA denotes dephosphorylation
T-27 873-878 GENE denotes STAT5
T-28 922-938 GENE denotes SHP-2-associated
T-29 939-948 DISEASE denotes leukemias
T-30 964-974 REG denotes attributed
T-31 982-991 POSREG denotes increased
T-32 992-1010 MPA denotes catalytic activity
T-33 1014-1017 POSREG denotes GOF
T-34 1018-1024 VAR denotes mutant
T-35 1025-1030 GENE denotes SHP-2
T-36 1032-1035 POSREG denotes GOF
T-37 1036-1042 VAR denotes mutant
T-38 1043-1048 GENE denotes SHP-2
T-39 1059-1065 POSREG denotes gained
T-40 1131-1138 REG denotes effects
T-41 1144-1147 POSREG denotes GOF
T-42 1148-1156 VAR denotes mutation
T-43 1160-1165 GENE denotes SHP-2
T-44 1167-1172 GENE denotes SHP-2
T-45 1173-1177 VAR denotes E76K
T-46 1182-1209 CPA denotes hematopoietic cell function
T-47 1283-1288 GENE denotes SHP-2
T-48 1314-1319 GENE denotes SHP-2
T-49 1320-1333 VAR denotes E76K mutation
T-50 1334-1340 REG denotes caused
T-51 1341-1367 DISEASE denotes myeloproliferative disease
T-52 1404-1409 GENE denotes SHP-2
T-53 1410-1419 NEGREG denotes decreased
T-54 1420-1443 CPA denotes hematopoietic potential
T-55 1494-1507 VAR denotes E76K mutation
T-56 1548-1557 POSREG denotes increased
T-57 1558-1570 INTERACTION denotes interactions
T-58 1574-1580 VAR denotes mutant
T-59 1581-1586 GENE denotes SHP-2
T-60 1592-1596 GENE denotes Grb2
T-61 1598-1602 GENE denotes Gab2
T-62 1608-1611 GENE denotes p85
T-63 1613-1620 REG denotes leading
T-64 1624-1639 POSREG denotes hyperactivation
T-65 1748-1756 POSREG denotes increase
T-66 1764-1782 MPA denotes catalytic activity
T-67 1784-1801 MPA denotes dephosphorylation
T-68 1805-1810 GENE denotes STAT5
T-69 1814-1819 GENE denotes SHP-2
T-70 1820-1824 VAR denotes E76K
T-71 1829-1837 NEGREG denotes dampened
T-72 1866-1874 NEGREG denotes inactive
T-73 1875-1880 GENE denotes SHP-2
T-74 1881-1885 VAR denotes E76K
T-75 1905-1919 VAR denotes C459S mutation
T-76 1947-1955 POSREG denotes increase
T-77 1960-1971 INTERACTION denotes interaction
T-78 1977-1981 GENE denotes Gab2
T-79 1989-1996 POSREG denotes enhance
T-80 2019-2031 PATHWAY denotes PI3K pathway
T-81 2095-2103 POSREG denotes elevated
T-82 2104-2122 MPA denotes catalytic activity
T-83 2136-2143 REG denotes changes
T-84 2196-2202 VAR denotes mutant
T-85 2203-2208 GENE denotes SHP-2
T-86 2237-2241 REG denotes play
T-87 2255-2259 REG denotes role
T-88 2263-2276 GENE denotes SHP-2-related
T-89 2277-2291 DISEASE denotes leukemigenesis
R-0 T-0 T-2 CauseOf Effects,mutation
R-1 T-0 T-3 ThemeOf Effects,SHP-2 phosphatase
R-10 T-4 T-13 CauseOf Mutations,hypersensitivity
R-100 T-56 T-58 CauseOf increased,mutant
R-101 T-56 T-63 CauseOf increased,leading
R-102 T-56 T-64 CauseOf increased,hyperactivation
R-103 T-57 T-58 ThemeOf interactions,mutant
R-104 T-57 T-59 ThemeOf interactions,SHP-2
R-105 T-57 T-60 ThemeOf interactions,Grb2
R-106 T-57 T-61 ThemeOf interactions,Gab2
R-107 T-57 T-62 ThemeOf interactions,p85
R-108 T-58 T-59 ThemeOf mutant,SHP-2
R-109 T-58 T-60 ThemeOf mutant,Grb2
R-11 T-5 T-10 A SHP-2 phosphatase,leukemias
R-110 T-58 T-61 ThemeOf mutant,Gab2
R-111 T-58 T-62 ThemeOf mutant,p85
R-112 T-58 T-63 CauseOf mutant,leading
R-113 T-58 T-64 CauseOf mutant,hyperactivation
R-114 T-63 T-64 CauseOf leading,hyperactivation
R-115 T-65 T-66 ThemeOf increase,catalytic activity
R-116 T-65 T-67 ThemeOf increase,dephosphorylation
R-117 T-65 T-68 ThemeOf increase,STAT5
R-118 T-65 T-69 ThemeOf increase,SHP-2
R-119 T-65 T-70 CauseOf increase,E76K
R-12 T-5 T-11 A SHP-2 phosphatase,juvenile myelomonocytic leukemia
R-120 T-65 T-71 CauseOf increase,dampened
R-121 T-66 T-67 ThemeOf catalytic activity,dephosphorylation
R-122 T-66 T-69 ThemeOf catalytic activity,SHP-2
R-123 T-66 T-71 ThemeOf catalytic activity,dampened
R-124 T-67 T-68 ThemeOf dephosphorylation,STAT5
R-125 T-67 T-69 ThemeOf dephosphorylation,SHP-2
R-126 T-67 T-70 ThemeOf dephosphorylation,E76K
R-127 T-67 T-71 ThemeOf dephosphorylation,dampened
R-128 T-68 T-70 ThemeOf STAT5,E76K
R-129 T-68 T-71 ThemeOf STAT5,dampened
R-13 T-6 T-8 ThemeOf cause,catalytic activity
R-130 T-69 T-70 ThemeOf SHP-2,E76K
R-131 T-69 T-71 ThemeOf SHP-2,dampened
R-132 T-72 T-73 ThemeOf inactive,SHP-2
R-133 T-72 T-74 CauseOf inactive,E76K
R-134 T-72 T-75 CauseOf inactive,C459S mutation
R-135 T-72 T-76 CauseOf inactive,increase
R-136 T-72 T-79 CauseOf inactive,enhance
R-137 T-73 T-74 ThemeOf SHP-2,E76K
R-138 T-73 T-75 ThemeOf SHP-2,C459S mutation
R-139 T-73 T-77 ThemeOf SHP-2,interaction
R-14 T-6 T-10 ThemeOf cause,leukemias
R-140 T-74 T-76 CauseOf E76K,increase
R-141 T-74 T-79 CauseOf E76K,enhance
R-142 T-75 T-76 CauseOf C459S mutation,increase
R-143 T-75 T-79 CauseOf C459S mutation,enhance
R-144 T-76 T-77 ThemeOf increase,interaction
R-145 T-76 T-78 ThemeOf increase,Gab2
R-146 T-76 T-79 CauseOf increase,enhance
R-147 T-77 T-78 ThemeOf interaction,Gab2
R-148 T-77 T-79 ThemeOf interaction,enhance
R-149 T-77 T-80 ThemeOf interaction,PI3K pathway
R-15 T-6 T-11 ThemeOf cause,juvenile myelomonocytic leukemia
R-150 T-79 T-80 ThemeOf enhance,PI3K pathway
R-151 T-81 T-82 ThemeOf elevated,catalytic activity
R-152 T-81 T-83 CauseOf elevated,changes
R-153 T-81 T-84 CauseOf elevated,mutant
R-154 T-81 T-86 CauseOf elevated,play
R-155 T-82 T-83 ThemeOf catalytic activity,changes
R-156 T-83 T-84 CauseOf changes,mutant
R-157 T-83 T-85 ThemeOf changes,SHP-2
R-158 T-83 T-86 CauseOf changes,play
R-159 T-83 T-87 CauseOf changes,role
R-16 T-7 T-8 ThemeOf hyperactivation,catalytic activity
R-160 T-83 T-88 CauseOf changes,SHP-2-related
R-161 T-83 T-89 ThemeOf changes,leukemigenesis
R-162 T-84 T-85 ThemeOf mutant,SHP-2
R-163 T-84 T-86 CauseOf mutant,play
R-164 T-84 T-87 CauseOf mutant,role
R-165 T-85 T-86 ThemeOf SHP-2,play
R-166 T-85 T-87 ThemeOf SHP-2,role
R-167 T-86 T-87 ThemeOf play,role
R-168 T-86 T-88 CauseOf play,SHP-2-related
R-169 T-86 T-89 ThemeOf play,leukemigenesis
R-17 T-7 T-9 ThemeOf hyperactivation,identified
R-170 T-87 T-88 ThemeOf role,SHP-2-related
R-171 T-87 T-89 ThemeOf role,leukemigenesis
R-18 T-7 T-10 ThemeOf hyperactivation,leukemias
R-19 T-7 T-11 ThemeOf hyperactivation,juvenile myelomonocytic leukemia
R-2 T-1 T-2 CauseOf gain-of-function,mutation
R-20 T-8 T-9 ThemeOf catalytic activity,identified
R-21 T-8 T-12 ThemeOf catalytic activity,characterized
R-22 T-8 T-13 ThemeOf catalytic activity,hypersensitivity
R-23 T-9 T-10 ThemeOf identified,leukemias
R-24 T-9 T-11 ThemeOf identified,juvenile myelomonocytic leukemia
R-25 T-9 T-12 ThemeOf identified,characterized
R-26 T-10 T-12 ThemeOf leukemias,characterized
R-27 T-10 T-13 ThemeOf leukemias,hypersensitivity
R-28 T-11 T-12 ThemeOf juvenile myelomonocytic leukemia,characterized
R-29 T-11 T-13 ThemeOf juvenile myelomonocytic leukemia,hypersensitivity
R-3 T-1 T-3 ThemeOf gain-of-function,SHP-2 phosphatase
R-30 T-12 T-13 ThemeOf characterized,hypersensitivity
R-31 T-14 T-16 CauseOf gain-of-function,mutations
R-32 T-14 T-18 CauseOf gain-of-function,induce
R-33 T-15 T-16 CauseOf GOF,mutations
R-34 T-15 T-17 ThemeOf GOF,SHP-2
R-35 T-15 T-18 CauseOf GOF,induce
R-36 T-16 T-17 ThemeOf mutations,SHP-2
R-37 T-16 T-18 CauseOf mutations,induce
R-38 T-17 T-18 ThemeOf SHP-2,induce
R-39 T-17 T-19 A SHP-2,hematopoietic malignancies
R-4 T-2 T-3 ThemeOf mutation,SHP-2 phosphatase
R-40 T-18 T-19 ThemeOf induce,hematopoietic malignancies
R-41 T-21 T-22 ThemeOf overexpression,SHP-2
R-42 T-21 T-23 CauseOf overexpression,attenuates
R-43 T-21 T-25 CauseOf overexpression,accelerated
R-44 T-22 T-23 ThemeOf SHP-2,attenuates
R-45 T-23 T-24 ThemeOf attenuates,hematopoietic cell function
R-46 T-23 T-25 CauseOf attenuates,accelerated
R-47 T-25 T-26 ThemeOf accelerated,dephosphorylation
R-48 T-25 T-27 ThemeOf accelerated,STAT5
R-49 T-26 T-27 ThemeOf dephosphorylation,STAT5
R-5 T-4 T-5 ThemeOf Mutations,SHP-2 phosphatase
R-50 T-28 T-31 CauseOf SHP-2-associated,increased
R-51 T-29 T-30 ThemeOf leukemias,attributed
R-52 T-29 T-35 A leukemias,SHP-2
R-53 T-30 T-32 ThemeOf attributed,catalytic activity
R-54 T-30 T-33 CauseOf attributed,GOF
R-55 T-30 T-34 CauseOf attributed,mutant
R-56 T-31 T-32 ThemeOf increased,catalytic activity
R-57 T-31 T-33 CauseOf increased,GOF
R-58 T-31 T-34 CauseOf increased,mutant
R-59 T-31 T-35 ThemeOf increased,SHP-2
R-6 T-4 T-6 CauseOf Mutations,cause
R-60 T-32 T-33 ThemeOf catalytic activity,GOF
R-61 T-32 T-34 ThemeOf catalytic activity,mutant
R-62 T-32 T-35 ThemeOf catalytic activity,SHP-2
R-63 T-33 T-34 CauseOf GOF,mutant
R-64 T-33 T-35 ThemeOf GOF,SHP-2
R-65 T-34 T-35 ThemeOf mutant,SHP-2
R-66 T-36 T-37 CauseOf GOF,mutant
R-67 T-36 T-38 ThemeOf GOF,SHP-2
R-68 T-36 T-39 CauseOf GOF,gained
R-69 T-37 T-38 ThemeOf mutant,SHP-2
R-7 T-4 T-7 CauseOf Mutations,hyperactivation
R-70 T-37 T-39 CauseOf mutant,gained
R-71 T-38 T-39 ThemeOf SHP-2,gained
R-72 T-40 T-41 ThemeOf effects,GOF
R-73 T-40 T-42 CauseOf effects,mutation
R-74 T-40 T-43 ThemeOf effects,SHP-2
R-75 T-40 T-44 ThemeOf effects,SHP-2
R-76 T-40 T-46 ThemeOf effects,hematopoietic cell function
R-77 T-41 T-42 CauseOf GOF,mutation
R-78 T-41 T-43 ThemeOf GOF,SHP-2
R-79 T-41 T-44 ThemeOf GOF,SHP-2
R-8 T-4 T-9 CauseOf Mutations,identified
R-80 T-41 T-45 CauseOf GOF,E76K
R-81 T-41 T-46 ThemeOf GOF,hematopoietic cell function
R-82 T-42 T-43 ThemeOf mutation,SHP-2
R-83 T-42 T-44 ThemeOf mutation,SHP-2
R-84 T-42 T-47 ThemeOf mutation,SHP-2
R-85 T-43 T-45 ThemeOf SHP-2,E76K
R-86 T-44 T-45 ThemeOf SHP-2,E76K
R-87 T-45 T-47 ThemeOf E76K,SHP-2
R-88 T-48 T-49 ThemeOf SHP-2,E76K mutation
R-89 T-48 T-51 A SHP-2,myeloproliferative disease
R-9 T-4 T-12 CauseOf Mutations,characterized
R-90 T-49 T-50 CauseOf E76K mutation,caused
R-91 T-49 T-53 CauseOf E76K mutation,decreased
R-92 T-50 T-51 ThemeOf caused,myeloproliferative disease
R-93 T-52 T-53 ThemeOf SHP-2,decreased
R-94 T-53 T-54 ThemeOf decreased,hematopoietic potential
R-95 T-55 T-56 CauseOf E76K mutation,increased
R-96 T-55 T-59 ThemeOf E76K mutation,SHP-2
R-97 T-55 T-63 CauseOf E76K mutation,leading
R-98 T-55 T-64 CauseOf E76K mutation,hyperactivation
R-99 T-56 T-57 ThemeOf increased,interactions